{"commentary":{"count":124,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":79,"youtube":22,"podcast":18,"x_video":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04819100\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"LIBRETTO-432","nct_id":"NCT04819100","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=libretto-432-nct04819100. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"LIBRETTO-432","arms":[{"description":"Selpercatinib administered orally.","label":"Selpercatinib","type":"EXPERIMENTAL"},{"description":"Placebo administered orally.","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":["Loxo Oncology, Inc."],"completion_date":{"date":"2028-05","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":152,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Selpercatinib","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2026-03-04","lead_sponsor":"Eli Lilly and Company","official_title":"LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-01-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-Free Survival (EFS)","timeFrame":"Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years)"}],"references":[{"citation":"Wu YL, Hochmair M, Yang Y, Yang XN, Tsuboi M, Paz-Ares L, Yang JC, Wu L, Kim HR, Rieke DT, Johnson M, Besse B, Sharma N, Maeda P, Peterson P, Lin BK, Frimodt-Moller B, Goldman J, Drilon A; LIBRETTO-432 Trial Investigators. Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2026 May 31. doi: 10.1056/NEJMoa2602628. Online ahead of print.","pmid":"42223087","type":"DERIVED"},{"citation":"Tsuboi M, Goldman JW, Wu YL, Johnson ML, Paz-Ares L, Yang JC, Besse B, Su W, Chao BH, Drilon A. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer. Future Oncol. 2022 Sep;18(28):3133-3141. doi: 10.2217/fon-2022-0656. Epub 2022 Aug 11.","pmid":"35950566","type":"DERIVED"}],"start_date":{"date":"2021-12-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT04819100"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/libretto-432-nct04819100"}